- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Adherence among chronic disease patients can lead to big savings
- Amylin's lipodystrophy treatment granted orphan-drug, fast-track designations
- Fatty liver may impose diabetes risk
- Pfizer forms licensing agreement with Seattle Genetics
SAN DIEGO — Amylin Pharmaceuticals and Takeda Pharmaceutical have halted development of a treatment for obesity in mid-stage clinical trials, the two companies said.
The companies said the decision to discontinue development of a therapy that combines pramlintide and metreleptin was based on "a commercial reassessment of the pramlintide/metreleptin program … [that] took into account a revised development plan, as well as evolving dynamics within he obesity therapeutic area."
Nevertheless, the companies said they would continue investigating other treatments for obesity.